Transcatheter aortic valve implantation has rapidly evolved over the past decade and may become the dominant therapy for aortic stenosis.
TAVI has rapidly evolved over the past decade and may become the dominant therapy for aortic stenosis in the future.
It is two decades since the first report of transcatheter implantation of a stented aortic valve in an animal. The first implantation of a transcatheter aortic valve in a human was accomplished just one decade ago dramatically demonstrating the promise and feasibility of this new therapy. Over the past 10 years, there have been rapid developments in valves, delivery systems and technical approaches. Today, transcatheter valve implantation is a technical possibility for the great majority of patients with aortic stenosis. The next 10 years may well see this become the dominant therapy for aortic stenosis.
Webb et al. (Thu,) conducted a review in Aortic stenosis. Transcatheter aortic valve implantation was evaluated. Transcatheter aortic valve implantation has rapidly evolved over the past decade and may become the dominant therapy for aortic stenosis.